A diabetic woman almost died from the “world’s most dangerous eating disorder” after doctors mistook her insulin misuse for “laziness”. April Longe, a 19-year-old a psychology student at ...

© 2024 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and ...

Air pollution has become a never ending problem world wide affecting the healths of millions. While its impact on respiratory and cardiovascular health is well-documented, emerging research ...

Ozempic maker Novo Nordisk A/S took two large steps toward meeting demand for its blockbuster drugs, committing 8.5 billion kroner ($1.2 billion) to build a new factory in Denmark shortly after it ...

GLP-1 agonists have taken the pharma world by storm, and Novo Nordisk has been at the forefront of it all thanks to blockbuster drug semaglutide, which it sells as Ozempic, Wegovy and Rybelsus.

Dec 18 (Reuters) - Novo Holdings, the controlling shareholder of Novo Nordisk (NOVOb.CO), opens new tab, on Wednesday sealed its $16.5 billion deal for Catalent (CTLT.N), opens new tab, as the ...

Novo Nordisk (NVO) stock is tumbling 21% today after individuals who received the company's experimental weight-loss drug shed many fewer pounds than expected. Specifically, the weight of patients ...

The US Food and Drug Administration on Monday approved Hikma Pharmaceuticals’ generic version of Novo Nordisk’s diabetes drug, Victoza, clearing the way for the launch of another copy of the ...

(Reuters) - All regulatory closing conditions related to Novo Holdings' $16.5 billion acquisition of U.S. contract drug maker Catalent had been fulfilled, the companies said on Saturday, adding ...

Novo Holdings will proceed with its $16.5 billion acquisition of Catalent, the companies announced Saturday, after the Federal Trade Commission decided not to challenge the deal. It’s expected to ...

After clearing all regulatory hurdles associated with its proposed buyout of CDMO Catalent, Novo Holdings is nearly ready to unwrap its $16.5 billion present just in time for the holidays.

Novo Nordisk recently announced results for a new weight loss candidate, CagriSema. Data from the trial underwhelmed investors, and Novo stock is down almost 20% on the news. However, investors ...